Comparison of clinical outcome between Nivolumab and Regorafenib as second-line systemic therapy after Sorafenib failure in patients with advanced hepatocellular carcinoma

被引：0
|
作者：
Lee, Jae Seung [1 ,2 ,3 ]
Lee, Hong Jun [4 ]
Lee, Hye Won [1 ,2 ,3 ]
Kim, Beom Kyung [1 ,2 ,3 ]
Kim, Seung Up [1 ,2 ,3 ]
Park, Jun Yong [1 ,2 ,3 ]
Ahn, Sang Hoon [1 ,2 ,3 ]
Kim, Do Young [1 ,2 ,3 ]
机构：
[1] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Inst Gastroenterol, Coll Med, Seoul, South Korea
[3] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Seoul, South Korea
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-148
引用
收藏
页码：S595 / S595
页数：1
相关论文
共 50 条
  • [1] COMPARISON OF CLINICAL OUTCOME BETWEEN NIVOLUMAB AND REGORAFENIB AS SECOND- LINE SYSTEMIC THERAPY AFTER SORAFENIB FAILURE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Lee, Jae Seung
    Lee, Hong Jun
    Lee, Hye Won
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Jun Yong
    Ahn, Sang Hoon
    Kim, Do Young
    HEPATOLOGY, 2023, 78 : S1820 - S1821
  • [2] Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
    Lee, Hong Jun
    Lee, Jae Seung
    So, Hyesung
    Yoon, Ja Kyung
    Choi, Jin-Young
    Lee, Hye Won
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Jun Yong
    Ahn, Sang Hoon
    Kim, Do Young
    YONSEI MEDICAL JOURNAL, 2024, 65 (07) : 371 - 379
  • [3] Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment
    Kuzuya, Teiji
    Ishigami, Masatoshi
    Ito, Takanori
    Ishizu, Yoji
    Honda, Takashi
    Ishikawa, Tetsuya
    Hirooka, Yoshiki
    Fujishiro, Mitsuhiro
    HEPATOLOGY RESEARCH, 2019, 49 (09) : 1054 - 1065
  • [4] Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
    Kuo, Yuan-Hung
    Yen, Yi-Hao
    Chen, Yen-Yang
    Kee, Kwong-Ming
    Hung, Chao-Hung
    Lu, Sheng-Nan
    Hu, Tsung-Hui
    Chen, Chien-Hung
    Wang, Jing-Houng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Survival Benefit of Nivolumab as a Second-Line Treatment After Failure of Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
    Odah, Hassan
    Alshammari, Kanan
    Alsobhi, Morooj
    Alshehri, Ahmed
    Alzanbaqi, Adnan
    Sanai, Faisal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S511 - S511
  • [6] Cost Effectiveness of Regorafenib as Second-Line Therapy for Patients With Advanced Hepatocellular Carcinoma
    Parikh, Neehar D.
    Singal, Amit G.
    Hutton, David W.
    CANCER, 2017, 123 (19) : 3725 - 3731
  • [7] Regorafenib as second-line therapy in hepatocellular carcinoma
    Duffy, Austin G.
    Greten, Tim F.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (03) : 141 - 142
  • [8] Regorafenib as second-line therapy in hepatocellular carcinoma
    Austin G. Duffy
    Tim F. Greten
    Nature Reviews Gastroenterology & Hepatology, 2017, 14 : 141 - 142
  • [9] Hepatocellular Carcinoma: Successes with Regorafenib in Second-line Therapy
    Weiss, Johannes
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2017, 55 (05):
  • [10] A study of cadonilimab combined with regorafenib as second-line or later therapy in patients with advanced hepatocellular carcinoma (aHCC)
    Qi, Qi
    Liu, Yang
    Li, Rentao
    Liu, Yayue
    Zhang, Xihao
    Lu, Wei
    Li, Huikai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345